# Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

> **NCT05834426** · — · NOT_YET_RECRUITING · sponsor: **Sociedad de Lucha Contra el Cáncer del Ecuador** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma, B-Cell
- Neoplasms
- Cancer
- High-grade B-cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Non Hodgkin Lymphoma
- Metabolomics

## Interventions

- **DIAGNOSTIC_TEST:** Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)

## Key facts

- **NCT ID:** NCT05834426
- **Lead sponsor:** Sociedad de Lucha Contra el Cáncer del Ecuador
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05834426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05834426, "Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05834426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*